Human Immune Responses Smallpox

Status Completed

Clinical Trial Summary

The purpose of this study is to attempt to identify the immune response of healthy adults to an investigational dilution of the Dryvax smallpox vaccine. In addition, we will try to determine whether certain genetic characteristics influence the size of the sore around the vaccination site, and use blood samples from subjects in the study to make a new form of antibody that could be given to people with vaccine side effects.

Clinical Trial Description

Smallpox is a very serious disease that is fatal in about 1 in 3 patients. Smallpox does not exist naturally in the world, and there have been no cases of smallpox in the world since 1980. Smallpox can be prevented through the use of a very effective vaccine called vaccinia virus (Dryvax). After the world was considered free of smallpox, the production of smallpox vaccine was discontinued, but due to the recent concern that the smallpox virus may be used as a means of bioterrorism, the production of the smallpox vaccine may be restarted. Although Dryvax is known to be an effective vaccine for the prevention of smallpox, very little is known about the ability of the body to develop defenses to prevent disease (immune responses) with this vaccine. As new vaccines for preventing smallpox are developed, it will be important to compare the immune responses they cause to the responses that occur with the standard vaccine, Dryvax. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Smallpox

Clinical Trial Details

NCT number	NCT00068198
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 1
Completion date	November 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05976100` - Study of the Safety, Tolerability, Pharmacokinetics of NIOCH-14 in Volunteers Aged 18-50 Years	Phase 1
Completed	`NCT01540929` - Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
Completed	`NCT00258947` - Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults	Phase 2
Completed	`NCT00189969` - Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects	Phase 1
Terminated	`NCT00053508` - Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination	Phase 2
Completed	`NCT01317238` - Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers	Phase 3
Completed	`NCT01056770` - Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers	Phase 3
Completed	`NCT00998543` - A Long-Term Study of Healthy Adults Vaccinated With One Dose of Smallpox Vaccine (LISTER Strain)	Phase 2
Withdrawn	`NCT00389103` - Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)	Phase 1
Terminated	`NCT00282581` - Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive	Phase 1
Completed	`NCT00133575` - ACAM 3000 MVA at Harvard Medical School	Phase 1/Phase 2
Active, not recruiting	`NCT00103584` - Safety and Immunogenicity Study of LC16m8, a Modified Smallpox Vaccine, in Healthy, Previously Unvaccinated Volunteers	Phase 1/Phase 2
Completed	`NCT00050505` - Expanded Dryvax Dilution Study in Previously Vaccinated Adults	Phase 2
Completed	`NCT05846243` - Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years	Phase 2/Phase 3
Completed	`NCT05935917` - Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults	Phase 1
Completed	`NCT00082446` - Combination Study With MVA BN and Dryvax	Phase 1
Completed	`NCT00038987` - Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT	Phase 1/Phase 2
Completed	`NCT05762523` - Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years	Phase 1
Completed	`NCT04971109` - Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Day	Phase 3
Completed	`NCT00646152` - Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study	Phase 1